Archives

img-01

Singapore Proposes Pharmaceutical Regulatory Changes

Singapore’s Health Sciences Authority (HSA) is planning to transfer regulatory control of drug products, currently regulated under the Medicines Act and the Poisons Act, to the Health Products Act. The HSA believes that this will help update, clarify and streamline Singapore’s existing... Read More

img-01

新加坡提议修改药品监管政策

新加坡卫生科学局(HSA)计划对药品注册的监管进行转移,从目前的在药品法和毒药法令的监管控制下,转移到保健品法案下进行管理。HSA认为,这将有助于使目前新加坡的药品注册监管更新,更透明和简化。 根据所提议的改变,药物将被称为“治疗产品”,定义为“一种保健产品,其预期用途是以治疗、预防、缓解或诊断为目的。”这一类别包括化学药和生物制品。 在这一监管举措的变更下,HSA将在保健品法案下实施四套附属法例。这项立法将涵盖药品生产、注册、临床试验、供应、进口、广告、不良事件报告和执法措施。一些规定将在此过程中被更新。HSA已经宣布,它将计划在2015年的第三季度实施这些新法规,。 Read More

img-01

Classification of General Medical Devices in Singapore

For more information about Singapore’s regulatory framework, please see Singapore Medical Device Regulations. You are welcome to use or share this infographic online or in your presentations and papers, as long as you include credits to Pacific Bridge Medical (www.pacificbridgemedical.com) and, if possible, a link... Read More

img-01

Heart Disease is on the Rise in Asia

Asians develop heart failure at an average age of 61, approximately a decade earlier than patients in the U.S. and Europe. Because many Asian patients do not understand the disease or the early stage symptoms, the five-year survival rate is very low.... Read More